Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01158118 · ClinicalTrials.gov registry record · Phase 2
Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors
A Phase 2 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT01158118 is a Phase 2 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 48 participants.
The verdict
NCT01158118, a Phase 2 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
This study will gather information about the combination the drugs plerixafor with sargramostim in donors of blood-forming cells (stem cells). These stem cells will be collected from the donor and transplanted into their sibling. The investigators believe that the two drugs together will provide enough stem cells for transplantation and may also reduce the risk of graft versus host disease.
Interventions
- DRUG Plerixafor
- DRUG Sargramostim
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2011-04-01 |
| Est. Completion | 2016-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01158118
The ClinicalTrials.gov registry entry for NCT01158118 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Plerixafor is the first listed.
NCT01158118 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01158118 about?
NCT01158118 is a clinical study titled "Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors". This study will gather information about the combination the drugs plerixafor with sargramostim in donors of blood-forming cells (stem cells). These stem cells will be collected from the donor and transplanted into their sibling. The investigators believe that the two drugs together will provide eno...
What is the current status of trial NCT01158118?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2011-04-01. Estimated completion is 2016-12-31.
What interventions are being tested in trial NCT01158118?
The interventions under investigation include: Plerixafor (DRUG), Sargramostim (DRUG).
Who is sponsoring clinical trial NCT01158118?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.